Page 39 - Lexaria Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lexaria Bioscience Corp.: Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. Study HYPER-A21-1 included three new "DehydraTECH 2.0" formulation variations designed to enable cannabidiol ("CBD") delivery perform...

Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 ACCESSWIRE Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. Study HYPER-A21-1 included three new 'DehydraTECH 2.0' formulation variations designed to enable ...

Shares of Lexaria Bioscience Corp. (NASDAQ: LEXX) got a boost, shooting 35% to $6.81 after the company disclosed successful results from first 2021 study, HYPER-A21-1. Sally Beauty Holdings, Inc. (NYSE: SBH) shares were also up, gaining 22% to $24.68 after the company reported better-than-expected Q2 results. Equities Trading DOWN James River Group Holdings, Ltd. (NASDAQ: JRVR) shares tumbled 31% to $31.97 after the company swung to a loss in the first quarter. The company also priced its 5.65 million share common stock offering at $31 per share. Shares of Yellow Corporation (NASDAQ: YELL...

Lexaria Bioscience Corp.: Lexaria Commences Human Clinical Hypertension Study TM CBD's ability to control blood pressure First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC / ACCESSWIRE / April 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway. Lexaria's patented DehydraTECH CBD formulation will be examined to assess its ability to control...

PCG Digital: Lexaria Bioscience: Turning the Tide on Hypertension New York, New York--(Newsfile Corp. - April 15, 2021) - PCG Digital -- Hypertension, or high blood pressure, is known as the "silent killer" because it causes more than 7 million deaths each year-often with next to no symptoms. Hypertension puts people at greater risk for heart disease and stroke, the leading causes of death in the United States, according to the Centers for Disease Control. Nearly half of adults in the United States have high blood pressure or are currently taking medication for hypertension-and very few have...